This site requires JavaScript and cookies to be enabled.

Qelbree represents a development in ADHD pharmacodynamics1

Qelbree is the first and only ADHD nonstimulant with a multimodal pharmacodynamic profile1-4*

 
Off-white spheres suspended by thin strings against a light gray background.

Qelbree integrates NE reuptake inhibition with serotonin (5‑HT2C) receptor modulation via partial agonism1

Ascending pathways transmit norepinephrine, dopamine, and serotonin upward from the lower brainstem, converging directly into the prefrontal cortex (PFC) before branching out across additional cortical regions.
Ascending pathways transmit norepinephrine, dopamine, and serotonin upward from the lower brainstem, converging directly into the prefrontal cortex (PFC) before branching out across additional cortical regions.

Qelbree interacts with the brain in multiple ways in the prefrontal cortex (PFC).1,5

Qelbree

  •  NET inhibition1†
    Qelbree binds to and inhibits NET (norepinephrine transporters)1
  •  Serotonin 5-HT2C partial agonist1
    Qelbree is the only ADHD treatment with serotonin receptor pharmacodynamics approved in FDA product labeling1,6*
  •  Qelbree is not a
    controlled substance1

Atomoxetine

  •  NET inhibition2

Psychostimulants

  •  NET inhibition7,8
  •  DAT inhibition7,8

Psychostimulants impact DAT in the areas of the brain associated with addiction and are controlled substances.9,10

*The pharmacodynamic activity of viloxazine is based on non-clinical studies and the clinical significance of the data is unknown. The mechanism of action of viloxazine in the treatment of ADHD is unclear; however, it is thought to be through inhibiting the reuptake of norepinephrine.1

†Inhibition of NET increases NE levels in the PFC.5

Abbreviations: ADHD, attention-deficit/hyperactivity disorder; DAT, dopamine transporter; NET, norepinephrine transporter.

 

Discover more:

Mechanism of delivery  Qelbree dosing  Switch to Qelbree 

Stay informed

Get Qelbree email updates, savings information, and links to helpful resources for you and your patients.

Sign up 

Background graphic

IMPORTANT SAFETY INFORMATION

INDICATION

Qelbree (viloxazine extended-release capsules) is indicated for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in adults and pediatric patients 6 years and older.

IMPORTANT SAFETY INFORMATION

WARNING: SUICIDAL THOUGHTS AND BEHAVIORS

In clinical studies, higher rates of suicidal thoughts and behaviors were reported in [read more] patients with ADHD treated with Qelbree than in patients treated with placebo. Closely monitor all Qelbree-treated patients for clinical worsening and for emergence of suicidal thoughts and behaviors.

In clinical studies, higher rates of suicidal thoughts and behaviors were reported in patients with ADHD treated with Qelbree than in patients treated with placebo. Closely monitor all [read more] Qelbree-treated patients for clinical worsening and for emergence of suicidal thoughts and behaviors.

CONTRAINDICATIONS

  • Concomitant administration of a monoamine oxidase inhibitor (MAOI), or dosing within 14 days after discontinuing an MAOI, because of an increased risk of hypertensive crisis
  • Concomitant administration of sensitive CYP1A2 substrates or CYP1A2 substrates with a narrow therapeutic range

WARNINGS & PRECAUTIONS

  • Suicidal thoughts and behaviors: Closely monitor all Qelbree-treated patients for clinical worsening and emergence of suicidal thoughts and behaviors, especially during the initial few months of drug therapy, and at times of dosage changes
  • Heart rate, blood pressure increases: Qelbree can cause an increase in diastolic blood pressure and heart rate. Assess these measures prior to starting therapy, following increases in dosage, and periodically during therapy
  • Activation of mania or hypomania: Noradrenergic drugs may induce a manic or mixed episode in patients with bipolar disorder. Prior to initiating treatment with Qelbree, screen patients to determine if they are at risk for bipolar disorder. Screening should include a detailed psychiatric history, including a personal or family history of suicide, bipolar disorder, and depression 
  • Somnolence and fatigue: Patients should not perform activities requiring mental alertness, such as operating a motor vehicle or hazardous machinery, due to potential somnolence (including sedation or lethargy) and fatigue, until they know how they will be affected by Qelbree 

ADVERSE REACTIONS

The most common adverse reactions (≥ 5% and at least twice the rate of placebo for any dose) in patients 6 to 17 years were somnolence, decreased appetite, fatigue, nausea, vomiting, insomnia, and irritability, and in adults, insomnia, headache, somnolence, fatigue, nausea, decreased appetite, dry mouth, and constipation. 

PREGNANCY

There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to Qelbree during pregnancy. Healthcare providers are encouraged to register patients by calling the National Pregnancy Registry for Psychiatric Medications at 1-866-961-2388 or by visiting www.womensmentalhealth.org/preg. 

Please see full Prescribing Information, including Boxed Warning.

References:

  • 1. Qelbree [package insert]. Rockville, MD: Supernus Pharmaceuticals, Inc.
  • 2. Strattera [package insert]. Indianapolis, IN: Lilly USA, LLC.
  • 3. Intuniv [package insert]. Lexington, MA: Takeda Pharmaceuticals U.S.A.
  • 4. Clonidine extended release tablets: package insert / prescribing info. Drugs.com. Updated December 13, 2025. Accessed June 24, 2026. https://www.drugs.com/pro/clonidine-extended-release-tablets.html
  • 5. Stahl SM. Stahl's Essential Psychopharmacology: Neuroscientific Basis and Practical Applications. 5th ed. Cambridge University Press; 2021. Accessed June 24, 2026. doi:10.1017/9781108975292
  • 6. Arnsten AFT. The emerging neurobiology of attention deficit hyperactivity disorder: the key role of the prefrontal association cortex. J Pediatr. 2009;154(5):I-S43. doi:10.1016/j.jpeds.2009.01.018
  • 7. Ritalin [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation.
  • 8. Adderall XR [package insert]. Horsham, PA: Teva Pharmaceuticals USA.
  • 9. Martin D, Le JK. Amphetamine. In: StatPearls. StatPearls Publishing; 2023. Accessed June 24, 2026. https://www.ncbi.nlm.nih.gov/books/NBK556103/
  • 10. Verghese C, Patel P, Abdijadid S. Methylphenidate. In: StatPearls. StatPearls Publishing; 2024. Accessed June 24, 2026. https://www.ncbi.nlm.nih.gov/books/NBK482451/

IMPORTANT SAFETY INFORMATION

INDICATION

Qelbree (viloxazine extended-release capsules) is indicated for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in adults and pediatric patients 6 years and older.

IMPORTANT SAFETY INFORMATION

WARNING: SUICIDAL THOUGHTS AND BEHAVIORS

In clinical studies, higher rates of suicidal thoughts and behaviors were reported in [read more] patients with ADHD treated with Qelbree than in patients treated with placebo. Closely monitor all Qelbree-treated patients for clinical worsening and for emergence of suicidal thoughts and behaviors.

In clinical studies, higher rates of suicidal thoughts and behaviors were reported in patients with ADHD treated with Qelbree than in patients treated with placebo. Closely monitor all [read more] Qelbree-treated patients for clinical worsening and for emergence of suicidal thoughts and behaviors.

CONTRAINDICATIONS

  • Concomitant administration of a monoamine oxidase inhibitor (MAOI), or dosing within 14 days after discontinuing an MAOI, because of an increased risk of hypertensive crisis
  • Concomitant administration of sensitive CYP1A2 substrates or CYP1A2 substrates with a narrow therapeutic range

WARNINGS & PRECAUTIONS

  • Suicidal thoughts and behaviors: Closely monitor all Qelbree-treated patients for clinical worsening and emergence of suicidal thoughts and behaviors, especially during the initial few months of drug therapy, and at times of dosage changes
  • Heart rate, blood pressure increases: Qelbree can cause an increase in diastolic blood pressure and heart rate. Assess these measures prior to starting therapy, following increases in dosage, and periodically during therapy
  • Activation of mania or hypomania: Noradrenergic drugs may induce a manic or mixed episode in patients with bipolar disorder. Prior to initiating treatment with Qelbree, screen patients to determine if they are at risk for bipolar disorder. Screening should include a detailed psychiatric history, including a personal or family history of suicide, bipolar disorder, and depression 
  • Somnolence and fatigue: Patients should not perform activities requiring mental alertness, such as operating a motor vehicle or hazardous machinery, due to potential somnolence (including sedation or lethargy) and fatigue, until they know how they will be affected by Qelbree 

ADVERSE REACTIONS

The most common adverse reactions (≥ 5% and at least twice the rate of placebo for any dose) in patients 6 to 17 years were somnolence, decreased appetite, fatigue, nausea, vomiting, insomnia, and irritability, and in adults, insomnia, headache, somnolence, fatigue, nausea, decreased appetite, dry mouth, and constipation. 

PREGNANCY

There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to Qelbree during pregnancy. Healthcare providers are encouraged to register patients by calling the National Pregnancy Registry for Psychiatric Medications at 1-866-961-2388 or by visiting www.womensmentalhealth.org/preg. 

Please see full Prescribing Information, including Boxed Warning.